Johnson & Johnson Joins Large-Cap Pharma Recovery with Imbruvica Royalties Monetized
Johnson & Johnson ranks among four large-cap pharmaceutical companies recommended for portfolio retention as the industry posts a 10.8% one-year gain and trades at a forward P/E of 18.7x. J&J’s Imbruvica royalties have been monetized by Royalty Pharma, which now holds payment rights for the leukemia treatment.
1. Industry Recovery and Valuation
The large-cap pharmaceutical sector has rebounded with a 10.8% increase over the past year and trades at a forward P/E of 18.7x versus the S&P 500’s 20.8x. Johnson & Johnson is highlighted alongside Eli Lilly, Sanofi and Bayer as core holdings due to strong quarterly results, robust pipeline activity and accelerated M&A deals.
2. Imbruvica Royalty Monetization
Royalty Pharma has acquired the rights to royalties from J&J’s Imbruvica, a chronic lymphocytic leukemia treatment, as part of its portfolio covering over 35 commercial biopharma products. This transaction shifts future payment streams from J&J to Royalty Pharma, affecting J&J’s long-term revenue mix.